Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for GlaxoSmithKline's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, GlaxoSmithKline's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
GlaxoSmithKline Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EGP 1.000000
2026-01-12
2026-01-13
2026-01-14
Cash Dividend
annually
EGP:EGP 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
GlaxoSmithKline's Trailing Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline (CAI:BIOC) has a Dividend Yield % of 1.47% as of Jun. 30, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Dividend Yield % too high?
GlaxoSmithKline's current Dividend Yield % is 1.47%. The Drug Manufacturers industry median Dividend Yield % is 2.04. GlaxoSmithKline's value of 1.47% is 27.9% below this industry median.
How does GlaxoSmithKline's Dividend Yield % compare to PRPH?
GlaxoSmithKline's Dividend Yield % of 1.47% can be compared against companies in the Drug Manufacturers industry. The industry median Dividend Yield % is 2.04. GlaxoSmithKline's value of 1.47% is 27.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.04, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline's current Dividend Yield % of 1.47% is 27.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on GlaxoSmithKline and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline's current Dividend Yield % is 1.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Dividend Yield % of 1.47%. The current Dividend Yield % is 1.47% and 27.9% below the Drug Manufacturers industry median of 2.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Dividend Yield % is 1.47% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:BIOC has been successfully added to your 